

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3993152

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
SEQUENCE:	3
CONVEYING PARTY DATA	
Name	Execution Date
N30 PHARMACEUTICALS, INC.	02/11/2015
RECEIVING PARTY DATA	
Name:	NIVALIS THERAPEUTICS, INC.
Street Address:	3122 STERLING CIRCLE
City:	BOULDER
State/Country:	COLORADO
Postal Code:	80301
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15228088
CORRESPONDENCE DATA	
Fax Number:	(303)268-0065
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3032680066
Email:	tcrispino@sbiplaw.com
Correspondent Name:	SWANSON & BRATSCHEUN, L.L.C.
Address Line 1:	8210 SOUTHPARK TERRACE
Address Line 4:	LITTLETON, COLORADO 80120
ATTORNEY DOCKET NUMBER:	0322.15PCT-US5 #3
NAME OF SUBMITTER:	ROSEMARY KELLOGG
SIGNATURE:	/Rosemary Kellogg/
DATE SIGNED:	08/04/2016
Total Attachments: 2	
source=DE-Corporate-Name-Change-Nivalis-Therapeutics-Inc#page1.tif	
source=DE-Corporate-Name-Change-Nivalis-Therapeutics-Inc#page2.tif	

Delaware

PAGE 1

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "N30 PHARMACEUTICALS, INC.", CHANGING ITS NAME FROM "N30 PHARMACEUTICALS, INC." TO "NIVALIS THERAPEUTICS, INC.", FILED IN THIS OFFICE ON THE ELEVENTH DAY OF FEBRUARY, A.D. 2015, AT 12:22 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COUNTY RECORDER OF DEEDS.

4321211 8100

150179767

You may verify this certificate online
at corp.delaware.gov/authver.shtml




Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 2113640

DATE: 02-11-15

PATENT
REEL: 039573 FRAME: 0418

**CERTIFICATE OF AMENDMENT
OF AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
N30 PHARMACEUTICALS, INC.**

N30 Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the "*Corporation*"), certifies as follows:

A. The name of the Corporation is N30 Pharmaceuticals, Inc. The predecessor to the Corporation, N30 Pharmaceuticals, LLC, was originally formed as a limited liability company under 18-201 of the Delaware Limited Liability Company Act on March 30, 2007. Effective as of 12:01 a.m. Eastern Standard Time on August 1, 2012, the Corporation's predecessor was converted in a Delaware corporation pursuant to a Certificate of Conversion filed with the Delaware Secretary of State on July 31, 2012. The Corporation's original Certificate of Incorporation was filed with the Delaware Secretary of State on July 31, 2012. The original Certificate of Incorporation was amended and restated by the Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware on September 23, 2014, which was amended and restated by the Second Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on November 18, 2014, which was amended and restated by the Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on February 9, 2015 (the "*Prior Certificate*").

B. This Certificate of Amendment of the Prior Certificate (this "*Certificate of Amendment*") was duly adopted by the Corporation's Board of Directors and stockholders in accordance with Sections 228 and 242 of the General Corporation Law of the State of Delaware and further amends the provisions of the Corporation's Certificate of Incorporation.

C. Article I of the Prior Certificate is hereby amended and restated in its entirety to read as follows:

ARTICLE I

The name of this corporation is Nivalis Therapeutics, Inc. (the "*Corporation*").

IN WITNESS WHEREOF, N30 Pharmaceuticals, Inc. has caused this Certificate of Amendment to be signed by Jon Congleton, a duly authorized officer of the Company, on February 11, 2015.

/s/Jon Congleton
Jon Congleton
Chief Executive Officer